# Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

> **NCT05533463** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 102 (actual)

## Conditions studied

- Advanced KRAS G12D Mutant Solid Tumors

## Interventions

- **DRUG:** HRS-4642

## Key facts

- **NCT ID:** NCT05533463
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-21
- **Primary completion:** 2024-06-25
- **Final completion:** 2025-12-30
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05533463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05533463, "Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05533463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*